Ireland - English - HPRA (Health Products Regulatory Authority)

chanelle medical unlimited company - escitalopram - oral drops, solution - 20 milligram(s)/millilitre - selective serotonin reuptake inhibitors; escitalopram

Ireland - English - HPRA (Health Products Regulatory Authority)

chanelle healthcare limited - escitalopram oxalate - oral drops solution - 20 mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

h. lundbeck a/s - escitalopram oxalate - oral drops solution - 20 mg/ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

lundbeck ltd - escitalopram oxalate - oral drops - 20mg/1ml

Ireland - English - HPRA (Health Products Regulatory Authority)

chanelle healthcare limited - escitalopram oxalate - oral drops solution - 20 base mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

h. lundbeck a/s - escitalopram - oral drops solution - 20

Australia - English - Department of Health (Therapeutic Goods Administration)

lundbeck australia pty ltd - escitalopram oxalate, quantity: 25.551 mg/ml (equivalent: escitalopram, qty 20 mg/ml) - oral liquid, solution - excipient ingredients: sodium hydroxide; ethanol; purified water; propyl gallate; citric acid - treatment of major depression. treatment of social anxiety disorder (social phobia). treatment of generalised anxiety disorder. treatment of obsessive-compulsive disorder.

Malta - English - Medicines Authority

wallace manufacturing chemists limited 51-53 stert street, abingdon, ox14 3jf, united kingdom - ascorbic acid, colecalciferol, dexpanthenol, nicotinamide, pyridoxine hydrochloride, thiamine hydrochloride, retinol palmitate, riboflavin, sodium ascorbate - oral drops, solution - ascorbic acid 19.35 mg colecalciferol 500 iu dexpanthenol 2 mg nicotinamide 12.5 mg pyridoxine hydrochloride 1 mg thiamine hydrochloride 2 mg retinol palmitate 5000 iu riboflavin 1 mg sodium ascorbate 34.44 mg - vitamins

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

wallace manufacturing chemists ltd - dexpanthenol; pyridoxine hydrochloride; nicotinamide; riboflavin sodium phosphate; thiamine hydrochloride; vitamin a; ergocalciferol; ascorbic acid; sodium ascorbate - oral drops - 4mg/1ml ; 2mg/1ml ; 25mg/1ml ; 2mg/1ml ; 4mg/1ml ; 10000unit/1ml ; 1000unit/1ml ; 38.7mg/1ml ; 68.88mg/1ml

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - ondansetron (unii: 4af302esos) (ondansetron - unii:4af302esos) - - prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥50 mg/m2 . - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. - prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. - prevention of postoperative nausea and/or vomiting. as with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and/or vomiting must be avoided postoperatively, ondansetron tablets usp and ondansetron orally disintegrating tablets usp are recommended even where the incidence of postoperative nausea and/or vomiting is low. the concomitant use of apomorphine with ondansetron is contraindicated based on reports of profound hypotension and los